CellsBin® Insight™
CellsBin® Insight™
Marrow-Level Insight. Detecting Rare Cells from Blood.
Monitoring multiple myeloma disease burden through detection of rare circulating malignant plasma cells across all stages of disease.
Multiple Myeloma
Burden and Risk Stratification
For research use only. Not for use in diagnostic procedures.
The unmet need
We Know the Target. We Can't See It.
Multiple myeloma lives in the bone marrow — but the marrow is hard to reach, and the picture it gives is a single point in space and time.
Invasive & infrequent
Bone-marrow biopsies are painful and can't be repeated often enough to follow a disease that moves.
A single snapshot
One aspiration samples one spot at one moment — missing heterogeneous, whole-body burden.
Invisible in blood
The malignant plasma cells that shed into blood are vanishingly rare and slip past conventional tests.
The solution
Transforming Invasive Bone Marrow Testing Into a Seamless Blood-Based Workflow
Insight enables longitudinal, blood-based visibility into disease burden across the multiple myeloma journey.
Validated performance
Ultra-Sensitive Detection With Clinical Confidence
Validated in a CLIA-certified laboratory to resolve disease when it matters most — down to a handful of cells in a milliliter of blood.
Lab Validation Results
Clinical utility
Designed to Inform Every Critical Decision
One blood-based assay, used across the arc of care — from the first treatment decision to long-term surveillance.
Risk at diagnosis
Establish baseline burden and risk to guide first-line treatment intensity.
Response monitoring
Track burden across cycles to see what's working — sooner, and without a biopsy.
Remission surveillance
Watch for residual disease and the earliest signs of return between visits.
Trials & research
Objective, repeatable endpoints and translational insight without serial marrow draws.
The difference
Better for Patients. Better for Decisions.
The reach of a biopsy, the ease of a blood test — with viable cells and single-cell biology that neither alternative can offer.
Workflow
From Blood Draw to Marrow-Level Insight
A simple, end-to-end experience — three steps between a routine blood draw and a decision-ready report.
- 01
A simple blood draw
One standard ~2 mL blood tube — no marrow biopsy, no special handling.
- 02
Rare cells isolated & analyzed
Our CLIA-certified lab captures rare circulating plasma cells and reads their single-cell biology.
- 03
Marrow-level report delivered
A decision-ready report: disease burden, trend, and risk stratification.
Advance Myeloma Care With Blood-Based Insight
Bring marrow-level intelligence to your clinic, trial, or translational program.